GARDP joins forces with University of Queensland to tackle serious bacterial infections
GARDP and the University of Queensland have announced an expansion of their partnership to tackle the growing global threat of serious bacterial infections.
Partners
GARDP signs MOU with Swiss Biotech BioVersys AG
GARDP has today announced an agreement with Swiss biopharmaceutical company BioVersys to explore opportunities to accelerate the research and development of antibiotics for serious bacterial infections.
Venatorx Pharmaceuticals and GARDP partner to develop new antibiotic for hospital acquired infections with limited treatment options
GARDP and Venatorx Pharmaceuticals today announced a collaboration to accelerate the development of cefepime-taniborbactam, an investigational combination of the fourth-generation antibiotic cefepime with taniborbactam, a novel, broad-spectrum beta-lactamase inhibitor that restores the activity of cefepime against carbapenem-resistant Enterobacterales (CRE) and carbapenem-resistant Pseudomonas aeruginosa (CRPA).
GARDP partners with Japanese pharmaceutical in pursuit of new antibiotics
GARDP has today announced an agreement with Daiichi Sankyo for GARDP to access and screen the Daiichi Sankyo chemical library. The library will be tested by Institut Pasteur Korea with the goal of discovering novel antibacterial compounds.
Dutch Ministry of Health, Welfare and Sport renews commitment to support GARDP
BERLIN – The Global Antibiotic Research and Development Partnership (GARDP) is pleased to announce continued support from the Dutch Ministry of Health, Welfare and Sport. … Dutch Ministry of Health, Welfare and Sport renews commitment to support GARDP
UK government invests in global partnership to treat gonorrhoea
BERLIN – Today the UK government announced £3.5 million of funding to develop new treatments for gonorrhoea. It will enable global access, including in low-and … UK government invests in global partnership to treat gonorrhoea
GARDP and Entasis Therapeutics initiate global phase 3 trial of zoliflodacin, a first-in-class oral antibiotic for the treatment of gonorrhoea
GARDP and Entasis Therapeutics (NASDAQ: ETTX) today jointly announced the initiation of a global phase 3 pivotal trial of zoliflodacin. Zoliflodacin is a novel, first-in-class oral antibiotic being developed for the treatment of uncomplicated gonorrhoea. Following positive phase 2 results previously published in the New England Journal of Medicine (NEJM), Entasis and GARDP have partnered to complete late stage development, with GARDP fully-funding and sponsoring the global phase 3 trial.
GARDP and FIND join ARC Research Hub on AMR
GENEVA – GARDP and FIND welcome the Australian Minister for Education’s announcement of AUD 5M to establish an Australian Research Council (ARC) Research Hub to … GARDP and FIND join ARC Research Hub on AMR
Government of Principality of Monaco supports GARDP’s efforts to tackle drug-resistant sepsis in newborns
Ut enim deleniti maiores aut quibusdam adipisci odio deleniti qui optio commodi laudantium rerum earum minima sed ea aut est voluptatem ad commodi enim voluptas dolor ut optio nemo consectetur quasi ut voluptatibus quo fugiat harum sit molestias et et labore corporis vitae ea voluptas sit et fugiat aliquam corrupti voluptatem et rem non cum est voluptas enim delectus laboriosam.
GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics
[Deutsch] GENEVA –The Global Antibiotic Research and Development Partnership (GARDP) is partnering with Calibr, the Helmholtz Centre for Infection Research (HZI), in particular its location … GARDP announces partnership with Calibr, HZI/HIPS and the University of Queensland in search for new antibiotics